1
|
Vimalnath KV, Rajeswari A, Dixit A, Chakravarty R, Sarma HD, Kulkarni S, Jha A, Puranik A, Rangarajan V, Goswami M, Chakraborty S. [ 90Y]Yttria Alumino Silicate Glass Microspheres: A Biosimilar Formulation to "TheraSphere" for Cost-Effective Treatment of Liver Cancer. Cancer Biother Radiopharm 2024; 39:82-91. [PMID: 38265675 DOI: 10.1089/cbr.2023.0118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024] Open
Abstract
Background: Selective internal radiation therapy (SIRT) using a suitable β--emitting radionuclide is a promising treatment modality for unresectable liver carcinoma. Yttrium-90 (90Y) [T1/2 = 64.2 h, Eβ(max) = 2.28 MeV, no detectable γ-photon] is the most preferred radioisotope for SIRT owing to its favorable decay characteristics. Objective: The present study describes indigenous development and evaluation of intrinsically radiolabeled [90Y]yttria alumino silicate ([90Y]YAS) glass microsphere, a formulation biosimilar to "TheraSphere" (commercially available, U.S. FDA-approved formulation), for SIRT of unresectable liver carcinoma in human patients. Methods: YAS glass microspheres of composition 40Y2O3-20Al2O3-40SiO2 (w/w) and diameter ranging between 20 and 36 μm were synthesized with almost 100% conversion efficiency and >99% sphericity. Intrinsically labeled [90Y]YAS glass microspheres were produced by thermal neutron irradiation of cold YAS glass microspheres in a research reactor. Subsequent to in vitro evaluations and in vivo studies in healthy Wistar rats, customized doses of [90Y]YAS glass microspheres were administered in human patients. Results: [90Y]YAS glass microspheres were produced with 137.7 ± 8.6 MBq/mg YAS glass (∼6800 Bq per microsphere) specific activity and 99.94% ± 0.02% radionuclidic purity at the end of irradiation. The formulation exhibited excellent in vitro stability in human serum and showed >97% retention in the liver up to 7 d post-administration when biodistribution studies were carried out in healthy Wistar rats. Yttrium-90 positron emission tomography scans recorded at different time points post-administration of customized dose of [90Y]YAS glass microspheres in human patients showed near-quantitative retention of the formulation in the injected lobe. Conclusions: The study confirmed the suitability of indigenously prepared [90Y]YAS glass microspheres for clinical use in the treatment of unresectable hepatocellular carcinoma.
Collapse
Affiliation(s)
- K V Vimalnath
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
| | - Ardhi Rajeswari
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
| | - Anupam Dixit
- Glass and Advance Materials Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
| | - Rubel Chakravarty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
| | - Haldhar D Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
| | - Suyash Kulkarni
- Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Centre, Parel, Mumbai, India
| | - Ashish Jha
- Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Centre, Parel, Mumbai, India
| | - Ameya Puranik
- Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Centre, Parel, Mumbai, India
| | - Venkatesh Rangarajan
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
- Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Centre, Parel, Mumbai, India
| | - Madhumita Goswami
- Glass and Advance Materials Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
| | - Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
| |
Collapse
|
2
|
Euprazia LA, Rajeswari A, Thyagharajan KK, Shanker NR. Type 1 and Type 2 Diabetes Measurement Using Human Face Skin Region. J Diabetes Res 2023; 2023:9931010. [PMID: 37794995 PMCID: PMC10547572 DOI: 10.1155/2023/9931010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 08/01/2023] [Accepted: 08/30/2023] [Indexed: 10/06/2023] Open
Abstract
Aim Analyse the diabetes mellitus (DM) of a person through the facial skin region using vision diabetology. Diabetes mellitus is caused by persistent high blood glucose levels and related complications, which show variation in facial skin regions due to reduced blood flow in the facial arteries. Materials and Method. In this study, 200 facial images of diabetes patients with skin conditions such as Bell's palsy, rubeosis faciei, scleroderma, and vitiligo were collected from existing face videos. Moreover, face images are collected from diabetic persons in India. Viola Jones' face-detecting algorithm extracts face skin regions from a diabetic person's face image in video frames. The affected skin area on the diabetic person's face is detected using HSV colour model segmentation. The proposed multiwavelet transform convolutional neural network (MWTCNN) extracts the features for diabetic measurement from up- and downfacial scaled images of diabetic persons. Results The existing deep learning models are compared with the proposed MWTCNN model, which provides the highest accuracy of 98.3%. Conclusion The facial skin region-based diabetic measurement avoids pricking of the serum and is used for continuous glucose monitoring.
Collapse
Affiliation(s)
- L. Aneesh Euprazia
- Computer Science and Engineering, Velammal Engineering College, Chennai, India
| | - A. Rajeswari
- Computer Science and Engineering, Velammal Engineering College, Chennai, India
| | - K. K. Thyagharajan
- Electronics and Communication Engineering, R.M.D Engineering College, Chennai, India
| | - N. R. Shanker
- Department of Computer Science and Engineering, Aalim Muhammed Salegh College of Engineering, Chennai, India
| |
Collapse
|
3
|
Chakraborty S, Vimalnath K, Rajeswari A. Experience on clinical scale formulation of ready to use [90Y] Y-hydroxyapatite microparticles utilizing 90Y produced in research reactor. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00303-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Chakraborty S, Vimalnath K, Rajeswari A, Goswami M, Chakravarty R, Sarma HD, Kulkarni S, Jha A, Rangarajan V. Indigenous preparation, quality control and evaluation of [90Y] Y-glass microspheres for treatment of liver cancer in India. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00378-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Chakravarty R, Rajeswari A, Shetty P, Jagadeesan KC, Ram R, Jadhav S, Sarma HD, Dash A, Chakraborty S. A simple and robust method for radiochemical separation of no-carrier-added 64Cu produced in a research reactor for radiopharmaceutical preparation. Appl Radiat Isot 2020; 165:109341. [PMID: 32745917 DOI: 10.1016/j.apradiso.2020.109341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 06/29/2020] [Accepted: 07/13/2020] [Indexed: 12/25/2022]
Abstract
Copper-64 is an excellent theranostic radiometal that is gaining renewed attention of the clinical community in the recent times. In order to meet the increasing demand of this radiometal, we have demonstrated the viability of its production via 64Zn (n,p) 64Cu reaction in a nuclear reactor. A semi-automated radiochemical separation module based on selective extraction of 64Cu as dithizonate complex was developed. The maximum available activity at the end of irradiation was ~ 700 MBq. The overall yield of 64Cu after the separation process was >85% and it could be obtained with ~12 GBq/μg specific activity, >99.9% radionuclidic purity and >98% radiochemical purity. The separated 64Cu could be utilized for preparation of a wide variety of radiopharmaceuticals.
Collapse
Affiliation(s)
- Rubel Chakravarty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India.
| | - Ardhi Rajeswari
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Priyalata Shetty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - K C Jagadeesan
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Ramu Ram
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Sachin Jadhav
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Haladhar Dev Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India
| | - Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India.
| |
Collapse
|
6
|
Vimalnath KV, Rajeswari A, Sarma HD, Dash A, Chakraborty S. Ce-141-labeled DOTMP: A theranostic option in management of pain due to skeletal metastases. J Labelled Comp Radiopharm 2019; 62:178-189. [PMID: 30663098 DOI: 10.1002/jlcr.3710] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 01/11/2019] [Accepted: 01/11/2019] [Indexed: 11/11/2022]
Abstract
Owing to its favorable radioactive decay characteristics (T1/2 = 32.51 d, Eβ [max] = 434.6 keV [70.5%] and 580.0 keV [29.5%], Eγ = 145.4 keV [48.5%]), 141 Ce could be envisaged as a theranostic radionuclide for use in nuclear medicine. The present article reports synthesis and evaluation of 141 Ce complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP) as a potent theranostic agent targeting metastatic skeletal lesions. Ce-141 was produced with 314 ± 29 MBq/mg (n = 6) specific activity and >99.9% radionuclidic purity (n = 6). Around 185 MBq dose of [141 Ce]Ce-DOTMP was synthesized with 98.6 ± 0.5% (n = 4) radiochemical yield under optimized conditions of reaction, and the preparation showed adequately high in vitro stability. Biodistribution studies in normal Wistar rats demonstrated significant skeletal localization and retention of injected activity (2.73 ± 0.28% and 2.63 ± 0.22% of injected activity per gram in femur at 3 hours and 14 days post-injection, respectively) with rapid clearance from non-target organs. The results of biodistribution studies were corroborated by serial scintigraphic imaging studies. These results demonstrate the potential utility of 141 Ce-DOTMP as a theranostic molecule for personalized patient care of cancer patients suffering from painful metastatic skeletal lesions.
Collapse
Affiliation(s)
- K V Vimalnath
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Ardhi Rajeswari
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Haladhar Dev Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
7
|
Affiliation(s)
- B. Bhuvaneshwari
- Department of Electronics and Communication Engineering, Coimbatore Institute of Technology, Coimbatore, India
| | - A. Rajeswari
- Department of Electronics and Communication Engineering, Coimbatore Institute of Technology, Coimbatore, India
| |
Collapse
|
8
|
Poongothai M, Subramanian PM, Rajeswari A. Design and implementation of IoT based smart laboratory. 2018 5th International Conference on Industrial Engineering and Applications (ICIEA) 2018. [DOI: 10.1109/iea.2018.8387090] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
|
9
|
Rajeswari A, Jackcina Stobel Christy E, Pius A. New insight of hybrid membrane to degrade Congo red and Reactive yellow under sunlight. Journal of Photochemistry and Photobiology B: Biology 2018; 179:7-17. [DOI: 10.1016/j.jphotobiol.2017.12.024] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Revised: 11/16/2017] [Accepted: 12/25/2017] [Indexed: 10/18/2022]
|
10
|
Chakraborty S, Vimalnath KV, Rajeswari A, Chakravarty R, Sarma HD, Radhakrishnan E, Kamaleshwaran K, Shinto AS, Dash A. A "mix-and-use" approach for formulation of human clinical doses of 177 Lu-DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases. J Labelled Comp Radiopharm 2017; 60:410-419. [PMID: 28477391 DOI: 10.1002/jlcr.3517] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 04/26/2017] [Accepted: 05/02/2017] [Indexed: 11/06/2022]
Abstract
Use of bone-seeking radiopharmaceuticals is an established modality in the palliative care of pain due to skeletal metastases. 177 Lu-DOTMP is a promising radiopharmaceutical for this application owing to the ideally suited decay properties of 177 Lu and excellent thermodynamic stability and kinetic rigidity of the macrocyclic complex. The aim of the present study is to develop a robust and easily adaptable protocol for formulation of clinical doses of 177 Lu-DOTMP at hospital radiopharmacy. After extensive radiochemical studies, an optimized strategy for formulation of clinical doses of 177 Lu-DOTMP was developed, which involves simple mixing of approximately 3.7 GBq of 177 Lu activity as 177 LuCl3 solution to an aqueous solution containing 5 mg of DOTMP and 8 mg of NaHCO3 . The proposed protocol yielded 177 Lu-DOTMP with >98% radiochemical purity, and the resultant formulation showed excellent in vitro stability and desired pharmacokinetic properties in animal model. Preliminary clinical investigations in 5 patients showed specific skeletal accumulation with preferential localization in the osteoblastic lesion sites and almost no uptake in soft tissue or any other major nontarget organ. The developed "mix-and-use" strategy would be useful for large number of nuclear medicine centers having access to 177 Lu activity and would thereby accelerate the clinical translation of 177 Lu-DOTMP.
Collapse
Affiliation(s)
- Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - K V Vimalnath
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - A Rajeswari
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - Rubel Chakravarty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - H D Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - E Radhakrishnan
- Nuclear Medicine and PET Services, Comprehensive Cancer Care Centre, Kovai Medical Centre and Hospital, Coimbatore, India
| | - K Kamaleshwaran
- Nuclear Medicine and PET Services, Comprehensive Cancer Care Centre, Kovai Medical Centre and Hospital, Coimbatore, India
| | - Ajit S Shinto
- Nuclear Medicine and PET Services, Comprehensive Cancer Care Centre, Kovai Medical Centre and Hospital, Coimbatore, India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India
| |
Collapse
|
11
|
Amalraj A, Suryaprabha T, Rajeswari A, Pius A. Photocatalytic Degradation of Quinalphos and Profenofos Pesticides Using UV Irradiated TiO 2 Nanoparticles—A Kinetic Study. ACTA ACUST UNITED AC 2016. [DOI: 10.1166/mat.2016.1365] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
12
|
Chakravarty R, Chakraborty S, Sarma HD, Nair KVV, Rajeswari A, Dash A. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation. J Labelled Comp Radiopharm 2016; 59:354-63. [PMID: 27264196 DOI: 10.1002/jlcr.3413] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2016] [Revised: 05/05/2016] [Accepted: 05/10/2016] [Indexed: 11/06/2022]
Abstract
Radiolabelled monoclonal antibodies (mAbs) are increasingly being utilized in cancer theranostics, which is a significant move toward tailored treatment for individual patients. Cetuximab is a recombinant, human-mouse chimeric IgG1 mAb that binds to the epidermal growth factor receptor with high affinity. We have optimized a protocol for formulation of clinically relevant doses (~2.22 GBq) of (90) Y-labelled Cetuximab and (177) Lu-labelled Cetuximab by conjugation of the mAb with a suitable bifunctional chelator, N-[(R)-2-amino-3-(paraisothiocyanato-phenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-N,N,N',N″,N″-pentaacetic acid (CHX-A″-DTPA). The radioimmunoconjugates demonstrated reasonably high specific activity (1.26 ± 0.27 GBq/mg for (90) Y-CHX-A″-DTPA-Cetuximab and 1.14 ± 0.15 GBq/mg for (177) Lu-CHX-A″-DTPA-Cetuximab), high radiochemical purity (>95%) and appreciable in vitro stability under physiological conditions. Preliminary biodistribution studies with both (90) Y-CHX-A″-DTPA-Cetuximab and (177) Lu-CHX-A″-DTPA-Cetuximab in Swiss mice bearing fibrosarcoma tumours demonstrated significant tumour uptake at 24-h post-injection (p.i.) (~16%ID/g) with good tumour-to-background contrast. The results of the biodistribution studies were further corroborated by ex vivo Cerenkov luminescence imaging after administration of (90) Y-CHX-A″-DTPA-Cetuximab in tumour-bearing mice. The tumour uptake at 24 h p.i. was significantly reduced with excess unlabelled Cetuximab, suggesting that the uptake was receptor mediated. The results of this study hold promise, and this strategy should be further explored for clinical translation.
Collapse
Affiliation(s)
- Rubel Chakravarty
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Sudipta Chakraborty
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Haladhar Dev Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - K V Vimalnath Nair
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Ardhi Rajeswari
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Ashutosh Dash
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| |
Collapse
|
13
|
Chakravarty R, Chakraborty S, Ram R, Nair KVV, Rajeswari A, Sarma HD, Dash A. Palliative care of bone pain due to skeletal metastases: Exploring newer avenues using neutron activated (45)Ca. Nucl Med Biol 2016; 43:140-9. [PMID: 26872438 DOI: 10.1016/j.nucmedbio.2015.10.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Accepted: 10/27/2015] [Indexed: 02/05/2023]
Abstract
INTRODUCTION With an objective to develop a cost-effective radiochemical formulation for palliation of pain due to skeletal metastases, we have demonstrated a viable method for large-scale production of (45)Ca (t½=163 days, Eβmax=0.3MeV) using moderate flux research reactor, its purification from radionuclidic impurities adopting electrochemical approach and preclinical evaluation of (45)CaCl2. METHODS Irradiation parameters were optimized by theoretical calculations for production of (45)Ca with highest possible specific activity along with minimum radionuclidic impurity burden. Based on this, the radioisotope was produced in reactor by irradiation of isotopically enriched (98% in (44)Ca) CaO target at a thermal neutron flux of ~1 × 10(14) n.cm(-2).s(-1) for 4 months. Scandium-46 impurity co-produced along with (45)Ca was efficiently removed adopting an electrochemical separation approach. The bone specificity of (45)CaCl2 was established by in vitro studies involving its uptake in hydroxyapatite (HA) particles and also evaluating its biodistribution pattern over a period of 2 weeks after in vivo administration in Wistar rats. RESULTS Thermal neutron irradiation of 100mg of enriched (98% in (44)Ca) CaO target followed by radiochemical processing and electrochemical purification procedure yielded ~37 GBq of (45)Ca with a specific activity of ~370 MBq/mg and radionuclidic purity>99.99%. The reliability and reproducibility of this approach were amply demonstrated by process demonstration in several batches. In vitro studies indicated significant uptake of (45)CaCl2 (up to 65%) in HA particles. In vivo biodistribution studies in Wistar rats showed specific skeletal accumulation (40-46%ID) with good retention over a period of 2 weeks. CONCLUSIONS To the best of our knowledge, this is the first study on utilization of (45)CaCl2 in the context of nuclear medicine. The results obtained in this study hold promise and warrant further investigations for future translation of (45)CaCl2 to the clinics, thereby potentially enabling a cost-effective approach for metastatic bone pain palliation especially in developing countries.
Collapse
Affiliation(s)
- Rubel Chakravarty
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400 085, India.
| | - Sudipta Chakraborty
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400 085, India
| | - Ramu Ram
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400 085, India
| | | | - Ardhi Rajeswari
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400 085, India
| | - Haladhar Dev Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400 085, India
| | - Ashutosh Dash
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400 085, India.
| |
Collapse
|
14
|
Chakraborty S, Sharma KS, Rajeswari A, Vimalnath KV, Sarma HD, Pandey U, Jagannath, Ningthoujam RS, Vatsa RK, Dash A. Radiolanthanide-loaded agglomerated Fe 3O 4 nanoparticles for possible use in the treatment of arthritis: formulation, characterization and evaluation in rats. J Mater Chem B 2015; 3:5455-5466. [PMID: 32262517 DOI: 10.1039/c5tb00677e] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
This investigation reports the preparation of agglomerated Fe3O4 nanoparticles and evaluation of its utility as a viable carrier in the preparation of radiolanthanides as potential therapeutic agents for the treatment of arthritis. The material was synthesized by a chemical route and characterized by XRD, FT-IR, SEM, EDX and TEM analysis. The surface of agglomerated particle possessed ion pairs (-O-:Na+) after dispersing particles in a NaHCO3 solution at pH = 7 which is conducive for radiolanthanide (*Ln = 90Y, 153Sm, 166Ho, 169Er, 177Lu) loading by replacement of Na+ ions with tripositive radiolanthanide ions. Radiolanthanide-loaded particulates exhibited excellent in vitro stability up to ∼3 half-lives of the respective lanthanide radionuclides when stored in normal saline at 37 °C. The radiochemical purities of the loaded particulates were found to be retained to the extent of >70% after 48 h of storage when challenged by a strong chelator DTPA present at a concentration as high as 5 mM, indicating fairly strong chemical association of lanthanides with agglomerated Fe3O4 nanoparticles. Biodistribution studies of 90Y and 166Ho-loaded particulates carried out after intra-articular injection into one of the knee joints of a normal Wistar rat revealed near-complete retention of the radioactive preparations (>98% of the administered radioactivity) within the joint cavity even after 72 h post injection. This was further confirmed by sequential whole-body radio-luminescence imaging. These experimental results are indicative of the potential use of radiolanthanide-loaded agglomerated Fe3O4 nanoparticles for the treatment of arthritis.
Collapse
Affiliation(s)
- Sudipta Chakraborty
- Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400 085, India.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Chakraborty S, Vimalnath KV, Rajeswari A, Sarma HD, Shinto A, Radhakrishnan ER, Dash A. Radiolanthanide-labeled HA particles in the treatment of rheumatoid arthritis: ready-to-use cold kits for rapid formulation in hospital radiopharmacy. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3309-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Chakraborty S, Vimalnath KV, Rajeswari A, Shinto A, Sarma HD, Kamaleshwaran K, Thirumalaisamy P, Dash A. Preparation, evaluation, and first clinical use of177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy. J Labelled Comp Radiopharm 2014; 57:453-62. [DOI: 10.1002/jlcr.3202] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Revised: 03/29/2014] [Accepted: 04/01/2014] [Indexed: 11/10/2022]
Affiliation(s)
- Sudipta Chakraborty
- Isotope Applications and Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai 400085 India
| | - K. V. Vimalnath
- Isotope Applications and Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai 400085 India
| | - A. Rajeswari
- Isotope Applications and Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai 400085 India
| | - Ajit Shinto
- Nuclear Medicine and PET Services; Comprehensive Cancer Care Centre; Kovai Medical Centre and Hospital; Coimbatore 641014 India
| | - H. D. Sarma
- Radiation Biology and Health Sciences Division; Bhabha Atomic Research Centre; Mumbai 400085 India
| | - K. Kamaleshwaran
- Nuclear Medicine and PET Services; Comprehensive Cancer Care Centre; Kovai Medical Centre and Hospital; Coimbatore 641014 India
| | - P. Thirumalaisamy
- Nuclear Medicine and PET Services; Comprehensive Cancer Care Centre; Kovai Medical Centre and Hospital; Coimbatore 641014 India
| | - Ashutosh Dash
- Isotope Applications and Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai 400085 India
| |
Collapse
|
17
|
Vimalnath KV, Rajeswari A, Chakraborty S, Dash A. Large scale production of ⁵¹Cr for medical application in a medium flux research reactor: a comparative investigation of Szilard-Chalmers process and direct (n,γ) route. Appl Radiat Isot 2014; 91:104-8. [PMID: 24926944 DOI: 10.1016/j.apradiso.2014.05.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Revised: 05/19/2014] [Accepted: 05/20/2014] [Indexed: 11/19/2022]
Abstract
The present article reports a systematic assessment on the reactor production of (51)Cr using the Szilard-Chalmers process as well as (50)Cr(n,γ)(51)Cr routes. In an attempt to select the most convenient path to undertake large-scale production of (51)Cr, the effectiveness of both the production routes on the basis of target selection, irradiated target processing, yield and specific activity of (51)Cr, was evaluated. An optimized (50)Cr(n,γ)(51)Cr production scheme offering (51)Cr of requisite purity is the positive outcome.
Collapse
Affiliation(s)
- K V Vimalnath
- Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400 085, India
| | - A Rajeswari
- Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400 085, India
| | - Sudipta Chakraborty
- Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400 085, India
| | - Ashutosh Dash
- Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400 085, India.
| |
Collapse
|
18
|
Kameswaran M, Vimalnath K, Rajeswari A, Joshi PV, Sarma H, Samuel G. Clinical scale preparation and evaluation of 131I-Rituximab for Non-Hodgkin's Lymphoma. RADIOCHIM ACTA 2014. [DOI: 10.1515/ract-2013-2148] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Radioimmunotherapy (RIT) with anti CD20 MoAb conjugated to a β
− emitting radioisotope like 131I or
90Y has the added advantage of delivering radiation not only to tumor cells that bind the antibody but also due to
a crossfire effect, to neighboring tumor cells inaccessible to the antibody. In order to make available an indigenous
radioimmunotherapeutic agent for Non Hodgkin's Lymphoma (NHL), radioiodinated Rituximab has been prepared and evaluated at a clinical
scale. Radioiodination of Rituximab was performed by the conventional Chloramine T method using 7.4 GBq Na131I
in a lead shielded plant. Six batches of radioiodination were prepared and characterized by electrophoresis and HPLC to evaluate the
reproducibility of the product. The product remained stable retaining the radiochemical purity > 95% upto 5 days after
radioiodination. In vitro cell binding studies and biodistribution studies in normal Swiss mice have indicated the potential
of this molecule as a radioimmunotherapeutic agent for NHL.
Collapse
Affiliation(s)
- Mythili Kameswaran
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | | | - Ardhi Rajeswari
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | | | - H. D. Sarma
- Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Grace Samuel
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| |
Collapse
|
19
|
Vimalnath KV, Shetty P, Rajeswari A, Chirayil V, Chakraborty S, Dash A. Reactor production of 32P for medical applications: an assessment of 32S(n,p)32P and 31P(n,γ)32P methods. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3115-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Karthick V, Ganesh Kumar V, Maiyalagan T, Deepa R, Govindaraju K, Rajeswari A, Stalin Dhas T. Green Synthesis of Well Dispersed Nanoparticles using Leaf Extract of Medicinally useful Adhatoda Vasica Nees. ACTA ACUST UNITED AC 2012. [DOI: 10.2174/1876402911204030192] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
21
|
Muthukumaran SS, Rajeswari A. 3.242 INHIBITION OF MONOAMINE OXIDASE-B BY CURCUMIN AND TETRAHYDROCURCUMIN IN THE MICE MODEL OF PARKINSON'S DISEASE. Parkinsonism Relat Disord 2012. [DOI: 10.1016/s1353-8020(11)70914-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
22
|
Ganesh Kumar V, Dinesh Gokavarapu S, Rajeswari A, Stalin Dhas T, Karthick V, Kapadia Z, Shrestha T, Barathy I, Roy A, Sinha S. Facile green synthesis of gold nanoparticles using leaf extract of antidiabetic potent Cassia auriculata. Colloids Surf B Biointerfaces 2011; 87:159-63. [DOI: 10.1016/j.colsurfb.2011.05.016] [Citation(s) in RCA: 214] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2011] [Revised: 05/05/2011] [Accepted: 05/08/2011] [Indexed: 11/28/2022]
|
23
|
Rajeswari A, Sabesan M. Neuropathological changes induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in male Swiss albino mice. Toxicol Ind Health 2008; 24:189-94. [DOI: 10.1177/0748233708093726] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We investigated the level of dopamine in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated male Swiss albino mice (40 mg/kg), after 7 days, we measured the levels of non-enzymatic antioxidants, the reduced glutothione (GSH), enzymatic anti-oxidants such as superoxide dismulase (SOD), cataloes (CAT) and also observed the histopathology of the mesencephalic areas after MPTP treatment by transmission electron microscopy (EM). We found that the MPTP treatment in mice caused a significant depletion of GSH, increased the specific activity of SOD, CAT, and thiobarbituric acid–reactive substances (TBARS) in mesencephalic region after 7 days of treatment, and decreased the striatal dopamine level to 75% by 7 days of MPTP treatment. The EM results also suggested that the mitochondrial alternation, nuclear membrane invagination, condensation of cytoplasm, vacuoles and perinuclear inclusion in the cytoplasm, and nuclear membrane disappearance were observed in MPTP-treated mice.
Collapse
Affiliation(s)
- A Rajeswari
- Department of Zoology, Annamalai University, Annamalai Nagar, Tamil Nadu, India
| | - M Sabesan
- Department of Zoology, Directorate of Distance Education, Annamalai University, Annamalai Nagar, Tamil Nadu, India
| |
Collapse
|
24
|
Rajeswari A. Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur Rev Med Pharmacol Sci 2006; 10:157-61. [PMID: 16910344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
We tested the hypothesis that curcumin, a polyphenolic antioxidant, acts as a powerful free radical scavenger in vivo in the brain, and interferes with oxidative stress caused by the parkinsonian neurotoxin, (MPTP) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. We measured the (GSH) reduced glutathione levels, (TBARS) glutathione lipid peroxidation, (CAT) catalase and (SOD) superoxide dismutase activity in the (ST) striatum and (MB) mid brain 3rd day and 7th day following MPTP and curcumin administration. MPTP treatment caused a significant depletion in GSH and increased the specific activity of SOD, CAT and lipid peroxidation in both ST and MB on the 3rd and 7th day. MPTP induced GSH depletion and lipid peroxidation in ST and MB was blocked by curcumin treatment. Curcumin exhibited a synergistic effect on SOD and CAT activities in the ST and MB regions. The present study provides direct evidence for the involvement of curcumin in neuroprotection against oxidative stress.
Collapse
Affiliation(s)
- A Rajeswari
- Research School Department of Zoology, Annamalai University, Annamalai Nagar, Chidambaram, South India.
| |
Collapse
|